Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era

被引：8
|
作者：
Hanzawa, Kyoko [1 ]
Momose, Shuji [2 ,3 ]
Higashi, Morihiro [2 ]
Tokuhira, Michihide [1 ]
Watanabe, Reiko [1 ]
Kajino, Kazunori [3 ]
Hino, Okio [3 ]
Itoyama, Shinji [2 ]
Kizaki, Masahiro [1 ]
Tamaru, Jun-Ichi [2 ]
机构：
[1] Saitama Med Univ, Dept Hematol, Saitama Med Ctr, Saitama, Japan
[2] Saitama Med Univ, Dept Pathol, Saitama Med Ctr, Saitama, Japan
[3] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo 113, Japan
来源：
LEUKEMIA & LYMPHOMA | 2010年 / 51卷 / 11期
关键词：
YB-1; diffuse large B-cell lymphoma; rituximab; P-glycoprotein; P-GLYCOPROTEIN EXPRESSION; HUMAN BREAST CANCERS; NUCLEAR EXPRESSION; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; R-CHOP; YB-1; CHEMOTHERAPY; DISEASE; LOCALIZATION;
D O I：
10.3109/10428194.2010.522285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The expression of YB-1 has been reported to predict poor clinical outcome in many human malignancies, including hematopoietic malignancies. In this study, we investigated the correlations between YB-1 expression and the clinicopathological features of patients with diffuse large B-cell lymphoma (DLBCL) in a single institution. The expression of YB-1 was analyzed in 168 cases by immunohistochemistry. Fifteen out of 168 cases (8.9%) showed cytoplasmic expression of YB-1. The expression of YB-1 was significantly associated with 5-year overall survival (OS) (p = 0.023). Rituximab plus CHOP therapy (n = 94) improved the 5-year survival rate in both YB-1-positive and -negative patients. In conclusion, the data presented in this report provide evidence that the cytoplasmic expression of YB-1 is a poor prognosis factor in DLBCL treated with CHOP therapy, whereas rituximab improves the survival of both YB-1-positive and -negative patients with DLBCL.
引用
收藏
页码：2054 / 2062
页数：9
相关论文
共 50 条
  • [1] Prognostication of diffuse large B-cell lymphoma in the rituximab era
    Ninan, Mary J.
    Wadhwa, Punit D.
    Gupta, Pankaj
    LEUKEMIA & LYMPHOMA, 2011, 52 (03) : 360 - 373
  • [2] Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era
    Nowakowski, Grzegorz S.
    Maurer, Matthew J.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Macon, William R.
    Ristow, Kay M.
    Allmer, Cristine
    Slager, Susan L.
    Witzig, Thomas E.
    Cerhan, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 412 - 417
  • [3] Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma
    Miao, Xiaobing
    Wu, Yaxun
    Wang, Yuchan
    Zhu, Xinghua
    Yin, Haibing
    He, Yunhua
    Li, Chunsun
    Liu, Yushan
    Lu, Xiaoyun
    Chen, Yali
    Shen, Rong
    Xu, Xiaohong
    He, Song
    EXPERIMENTAL CELL RESEARCH, 2016, 346 (02) : 157 - 166
  • [4] Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era
    Takahashi, Hiroyuki
    Tomita, Naoto
    Yokoyama, Masahiro
    Tsunoda, Saburo
    Yano, Takahiro
    Murayama, Kayoko
    Hashimoto, Chizuko
    Tamura, Kazuo
    Sato, Kazuya
    Ishigatsubo, Yoshiaki
    CANCER, 2012, 118 (17) : 4166 - 4172
  • [5] Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era
    Seki, Ritsuko
    Ohshima, Koichi
    Fujisaki, Tomoaki
    Uike, Naokuni
    Kawano, Fumio
    Gondo, Hisashi
    Makino, Shigeyoshi
    Eto, Tetsuya
    Moriuchi, Yukiyoshi
    Taguchi, Fumihiro
    Kamimura, Tomohiko
    Tsuda, Hiroyuki
    Ogawa, Ryosuke
    Shimoda, Kazuya
    Yamashita, Kiyoshi
    Suzuki, Keiko
    Suzushima, Hitoshi
    Tsukazaki, Kunihiro
    Higuchi, Masakazu
    Utsunomiya, Atae
    Iwahashi, Masahiro
    Imamura, Yutaka
    Tamura, Kazuo
    Suzumiya, Junji
    Yoshida, Minoru
    Abe, Yasunobu
    Matsumoto, Tadashi
    Okamura, Takashi
    CANCER SCIENCE, 2009, 100 (10): : 1842 - 1847
  • [6] Outcomes of Cardiac Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Al-Juhaishi, Taha
    Abu Zeinah, Ghaith
    Al-Kindi, Sadeer
    BLOOD, 2020, 136
  • [7] Primary breast diffuse large B-cell lymphoma in the era of rituximab
    Zhang, Na
    Cao, Caineng
    Zhu, Yuan
    Liu, Peng
    Liu, Luying
    Lu, Ke
    Luo, Jialin
    Zhou, Ning
    ONCOTARGETS AND THERAPY, 2016, 9 : 6093 - 6097
  • [8] Surmounting Chemoresistance by Targeting the Y-Box Binding Protein-1
    Inoue, Ikuyo
    Matsumoto, Ken
    Yu, Yingnan
    Bay, Boon-Huat
    ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY, 2012, 295 (02): : 215 - 222
  • [9] CLINICAL SIGNIFICANCE OF BIOMARKERS OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
    Niitsu, N.
    Hayama, M.
    Hagiwara, Y.
    Tanae, K.
    Kohri, M.
    Takahashi, N.
    ANNALS OF ONCOLOGY, 2011, 22 : 154 - 154
  • [10] Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era
    Al-Juhaishi, Taha
    Al-Kindi, Sadeer G.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 339 : 146 - 149
12345